Smith, 7, diagnosed with a rare blood disorder, receives a life-saving stem cell transplant from his father, Matt, offering ...

Rates of grade III/IV acute GVHD at 3 months were 3% with cyclophosphamide-cyclosporin prophylaxis and 10% with standard ...

Peripheral blood progenitor cells (PBPC) are increasingly being used instead of bone marrow in autologous transplantation for hematologic malignancies.1 This approach shortens the period of ...

Haematology's profound transformation offers new hope through advanced diagnostics, personalized medicine, and the noble act ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

Macadamia nuts have a rich nutritional profile. They are packed with healthy fats, which serve as a steady and long-lasting ...

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3 ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

INmune Bio's XPro1595 targets soluble TNF for Alzheimer's. Phase 2 results could reshape inflammatory disease treatment.